title: Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?
authors.affiliation: Medical Oncology, S. Chiara Hospital, Trento, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Maines
authors.affiliation: Medical Oncology, S. Chiara Hospital, Trento, Italy.
authors.forename: Antonello
authors.initials: A
authors.lastname: Veccia
authors.affiliation: Medical Oncology, S. Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
mesh_terms: D000069501:Abiraterone Acetate; D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D049268:Positron-Emission Tomography; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D019233:Retreatment
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate